Assessment of body composition, metabolism, and pulmonary function in patients with myotonic dystrophy type 1.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
09 Sep 2022
09 Sep 2022
Historique:
entrez:
10
9
2022
pubmed:
11
9
2022
medline:
14
9
2022
Statut:
ppublish
Résumé
Abnormal body composition in myotonic dystrophy type 1 (DM1) are affected by energy intake above resting energy expenditure (REE). We aim to investigate the characteristics and relationship between body composition, REE, and pulmonary function in patients with DM1, and to examine their changes in 1 year. The study design was a single-center, cross-sectional, and longitudinal study of body composition, REE characteristics, and pulmonary function. Twenty-one male patients with DM1 and 16 healthy volunteers were registered in the study. Body composition was measured using dual-energy X-ray absorptiometry (DEXA). Fat mass (FM) index (kg/m2), fat-FM index (kg/m2), and skeletal mass index (kg/m2) were calculated. The measurements were taken breath by breath with a portable indirect calorimeter. The REE was calculated using the oxygen intake (VO2) and carbon dioxide output (VCO2) in the Weir equation. Basal energy expenditure (BEE) was calculated by substituting height, weight, and age into the Harris-Benedict equation. The study enrolled male patients with DM1 (n = 12) and healthy male volunteers (n = 16). Patients with DM1 (n = 7) and healthy volunteers (n = 14) could be followed in 1 year. The body composition of patients with DM1 was significantly higher in the FM index and significantly lower in the fat-FM index and skeletal mass index. The REE of patients with DM1 was significantly lower and was not associated with body composition. Patients with DM1 had poor metabolism that was not related to body composition. FM was high and lean body mass was low.
Identifiants
pubmed: 36086756
doi: 10.1097/MD.0000000000030153
pii: 00005792-202209090-00084
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30412Informations de copyright
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no funding and conflicts of interest to disclose.
Références
Brook JD, McCurrach ME, Harley HG, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell. 1992;21:799–808.
Gagnon C, Noreau L, Moxley RT, et al. Towards an integrative approach to the management of myotonic dystrophy type 1. J Neurol Neurosurg Psychiatry. 2007;78:800–6.
Seijger CG, Drost G, Posma JM, et al. Overweight is an independent risk factor for reduced lung volumes in myotonic dystrophy type 1. PLoS One. 2016;11:1–11.
Barja S, Pérez R. Clinical assessment underestimates fat mass and overestimates resting energy expenditure in children with neuromuscular diseases. Clin Nutr ESPEN. 2016;15:11–5.
Daly JM, Heymsfield SB, Head CA, et al. Human energy requirements: overestimation by widely used prediction equation. Am J Clin Nutr. 1985;42:1170–4.
Bertoli S, De Amicis R, Mastella C, et al. Spinal muscular atrophy, types I and II: what are the differences in body composition and resting energy expenditure? Clin Nutr. 2017;36:1674–80.
Fiuza-Luces C, Santos-Lozano A, et al. Assessment of resting energy expenditure in pediatric mitochondrial diseases with indirect calorimetry. Clin Nutr. 2016;35:1484–9.
Dickerson RN, Brown RO, Gervasio JG, et al. Measured energy expenditure of tube-fed patients with severe neurodevelopmental disabilities. J Am Coll Nutr. 1999;18:61–8.
McCrory MA, Kim HR, Wright NC, et al. Energy expenditure, physical activity, and body composition of ambulatory adults with hereditary neuromuscular disease. Am J Clin Nutr. 1998;67:1162–9.
Elliott SA, Davidson ZE, Davies PS, et al. Predicting resting energy expenditure in boys with Duchenne muscular dystrophy. Eur J Paediatr Neurol. 2012;16:631–5.
Ceballos-Sáenz D, Zapata-Aldana E, Singeris S, et al. Body composition in patients with congenital myotonic dystrophy. Muscle Nerve. 2019;60:176–9.
Skalsky AJ, Han JJ, Abresch RT, et al. Regional and whole-body dual-energy X-ray absorptiometry to guide treatment and monitor disease progression in neuromuscular disease. Phys Med Rehabil Clin N Am. 2012;23:67–73, x.
Bernabe-García M, Rodríguez-Cruz M, Atilano S, et al. Body composition and body mass index in Duchenne muscular dystrophy: role of dietary intake. Muscle Nerve. 2019;59:295–302.
Martinez EE, Quinn N, Arouchon K, et al. Comprehensive nutritional and metabolic assessment in patients with spinal muscular atrophy: opportunity for an individualized approach. Neuromuscul Disord. 2018;28:512–9.
Heatwole C, Bode R, Johnson NE, et al. Myotonic dystrophy health index: correlations with clinical tests and patient function. Muscle Nerve. 2016;53:183–90.
Vuillerot C, Braillon P, Fontaine-Carbonnel S, et al. Influence of a two-year steroid treatment on body composition as measured by dual X-ray absorptiometry in boys with Duchenne muscular dystrophy. Neuromuscul Disord. 2014;24:467–73.
Poruk KE, Davis RH, Smart AL, et al. Observational study of caloric and nutrient intake, bone density, and body composition in infants and children with spinal muscular atrophy type I. Neuromuscul Disord. 2012;22:966–73.
Pruna L, Chatelin J, Pascal-Vigneron V, et al. Regional body composition and functional impairment in patients with myotonic dystrophy. Muscle Nerve. 2011;44:503–8.
Skalsky AJ, Han JJ, Abresch RT, et al. Assessment of regional body composition with dual-energy X-ray absorptiometry in Duchenne muscular dystrophy: correlation of regional lean mass and quantitative strength. Muscle Nerve. 2009;39:647–51.
Skalsky AJ, Abresch RT, Han JJ, et al. The relationship between regional body composition and quantitative strength in facioscapulohumeral muscular dystrophy (FSHD). Neuromuscul Disord. 2008;18:873–80.
Sproule DM, Montes J, Montgomery M, et al. Increased fat mass and high incidence of overweight despite low body mass index in patients with spinal muscular atrophy. Neuromuscul Disord. 2009;19:391–6.
Sedehizadeh S, Brook JD, Maddison P, et al. Body composition and clinical outcome measures in patients with myotonic dystrophy type 1. Neuromuscul Disord. 2017;27:286–9.
Kanda F, Fujii Y, Takahashi K, et al. Dual-energy X-ray absorptiometry in neuromuscular diseases. Muscle Nerve. 1994;17:431–5.
Palmieri GM, Bertorini TE, Griffin JW, et al. Assessment of whole body composition with dual energy x-ray absorptiometry in Duchenne muscular dystrophy: correlation of lean body mass with muscle function. Muscle Nerve. 1996;19:777–9.
Solbakken G, Bjørnarå B, Kirkhus E, et al. MRI of trunk muscles and motor and respiratory function in patients with myotonic dystrophy type 1. BMC Neurol. 2019;19:1–11.
Hawkins AM, Hawkins CL, Abdul Razak K, et al. Respiratory dysfunction in myotonic dystrophy type 1: a systematic review. Neuromuscul Disord. 2019;29:198–212.
Kaminsky P, Poussel M, Pruna L, et al. Organ dysfunction and muscular disability in myotonic dystrophy type 1. Medicine (Baltim). 2011;90:262–8.
Boussaïd G, Wahbi K, Laforet P, et al. Genotype and other determinants of respiratory function in myotonic dystrophy type 1. Neuromuscul Disord. 2018;28:222–8.
Saure C, Caminiti C, Weglinski J, et al. Energy expenditure, body composition, and prevalence of metabolic disorders in patients with Duchenne muscular dystrophy. Diabetes Metab Syndr. 2018;12:81–5.
Kosuke Y, Yoko A, Yasuhiro S, et al. Resting energy expenditure and regional body composition in myotonic dystrophy type 1 patients. J Asahikawa Med Cent. 2017;3:7–13.
Mathieu J, Boivin H, Meunier D, et al. Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology. 2001;56:336–40.
Dogan C, De Antonio M, Hamroun D, et al. Gender as a modifying factor influencing myotonic dystrophy type 1 phenotype severity and mortality: a nationwide multiple databases cross-sectional observational study. PLoS One. 2016;11:e01482641–12.
Perseghin G, Comola M, Scifo P, et al. Postabsorptive and insulin-stimulated energy and protein metabolism in patients with myotonic dystrophy type 1. Am J Clin Nutr. 2004;80:357–64.
Shimizu-Fujiwara M, Komaki H, Nakagawa E, et al. Decreased resting energy expenditure in patients with Duchenne muscular dystrophy. Brain Dev. 2012;34:206–12.
Gonzalez-Bermejo J, Lofaso F, Falaize L, et al. Resting energy expenditure in Duchenne patients using home mechanical ventilation. Eur Respir J. 2005;25:682–7.
Zanardi MC, Tagliabue A, Orcesi S, et al. Body composition and energy expenditure in Duchenne muscular dystrophy. Eur J Clin Nutr. 2003;57:273–8.
Jacques MF, Orme P, Smith J, et al. Resting energy expenditure in adults with Becker’s muscular dystrophy. PLoS One. 2017;12:e01698481–17.
Hogan SE. Body composition and resting energy expenditure of individuals with Duchenne and Becker muscular dystrophy. Can J Diet Pract Res. 2008;69:208–12.
Merlini L, Vagheggini A, Cocchi D, et al. Sarcopenia and sarcopenic obesity in patients with muscular dystrophy. Front Aging Neurosci. 2014;6:1–6.
Fujiwara T, Tanabe A, Tsuji T, et al. Activities of daily living (ADL) structure of patients with Duchenne muscular dystrophy, including adults. Keio J Med. 2009;58:223–6.
Weir JB. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol. J Physiol. 1949;109:1–9.
Harris JA, Benedict FG. A biometric study of human basal metabolism. Proc Natl Acad Sci USA. 1918;4:370–3.
Ignacio de UJ, González-Madroño A, de Villar NG, et al. CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp. 2005;20:38–45.
Cohen J. The significance of a product moment rs. Chap 3. In: Statistical power analysis for the behavioral sciences. 2nd ed, Hillsdale, NJ: Lawrence Erlbaum, the United States of America, 1988:75–108.
Wenninger S, Montagnese F, Schoser B, et al. Core clinical phenotypes in myotonic dystrophies. Front Neurol. 2018;9:1–9.
Geisler C, Braun W, Pourhassan M, et al. Age-dependent changes in resting energy expenditure (REE): insights from detailed body composition analysis in normal and overweight healthy Caucasians. Nutrients. 2016;8:3221–11.
Jozefowicz RF, Welle SL, Nair KS, et al. Basal metabolic rate in myotonic dystrophy: evidence against hypometabolism. Neurology. 1987;37:1021–5.
Hunter GR, Weinsier RL, Gower BA, et al. Age-related decrease in resting energy expenditure in sedentary white women: effects of regional differences in lean and fat mass. Am J Clin Nutr. 2001;73:333–7.
Elia M. Organ and tissue contribution to metabolic rate. Kinney J, Tucker H (eds): In: Energy metabolism – Tissue determinants and corollaries. New York: Raven Press; 1992;61:80.
Poussel M, Kaminsky P, Renaud P, et al. Supine changes in lung function correlate with chronic respiratory failure in myotonic dystrophy patients. Respir Physiol Neurobiol. 2014;193:43–51.
Fiz JA, Aguilar X, Carreres A, et al. Postural variation of the maximum inspiratory and expiratory pressures in obese patients. Int J Obes. 1991;15:655–9.
Palatini P, Julius S. Heart rate and the cardiovascular risk. J Hypertens. 1997;15:3–17.
Silva DAS, de Lima TR, Tremblay MS, et al. Association between resting heart rate and health related physical fitness in Brazilian adolescents. Biomed Res Int. 2018;2018:1–11.
Diaz A, Bourassa MG, Guertin MC, et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005;26:967–74.
Wahbi K, Porcher R, Laforêt P, et al. Development and validation of a new scoring system to predict survival in patients with myotonic dystrophy type 1. JAMA Neurol. 2018;75:573–81.
Tanawuttiwat T, Wagner KR, Tomaselli G, et al. Left ventricular dysfunction and conduction disturbances in patients with myotonic muscular dystrophy type I and II. JAMA Cardiol. 2017;2:225–8.
Ballo P, Giaccardi M, Colella A, et al. Mechanical and electrophysiological substrate for recurrent atrial flutter detected by right atrial speckle tracking echocardiography and electroanatomic mapping in myotonic dystrophy type 1. Circulation. 2013;127:1422–4.
Nazarian S, Bluemke DA, Wagner KR, et al. QRS prolongation in myotonic muscular dystrophy and diffuse fibrosis on cardiac magnetic resonance. Magn Reson Med. 2010;64:107–14.
Rakocevic Stojanovic V, Peric S, Lavrnic D, et al. Leptin and the metabolic syndrome in patients with myotonic dystrophy type 1. Acta Neurol Scand. 2010;121:94–8.
Peric S, Bozovic I, Nisic T, et al. Body composition analysis in patients with myotonic dystrophy types 1 and 2. Neurol Sci. 2019;40:1035–40.
Baumgartner RN, Wayne SJ, Waters DL, et al. Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. Obes Res. 2004;12:1995–2004.
Brown RJ, Araujo-Vilar D, Cheung PT, et al. The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab. 2016;101:4500–11.
Vujnic M, Peric S, Popovic S, et al. Metabolic syndrome in patients with myotonic dystrophy type 1. Muscle Nerve. 2015;52:273–7.